Yahoo

Stress Hives Can Be Itchy and Embarrassing — Here’s How To Speed Relief and Block Flare-Ups

If you notice red, itchy welts suddenly popping up on your skin, you may start to panic. Are you having an allergic reaction? Did you catch something contagious? But your mystery rash may have a much ...
Healio

Remibrutinib favorable despite past anti-IgE biologic use in chronic spontaneous urticaria

Among adults with chronic spontaneous urticaria inadequately controlled by H1 antihistamine treatment, remibrutinib improved ...

EU approves Sanofi and Regeneron’s Dupixent as first targeted therapy for chronic spontaneous urticaria in a decade

Dupixent has gained EU approval as the first targeted therapy in more than ten years for chronic spontaneous urticaria, ...
Healthline

Pressure Urticaria: Causes and Treatment

Pressure urticaria is a type of chronic urticaria that causes recurring hives from pressure applied to your skin. It may be treated with a combination of trigger avoidance and medications. Better ...
Yahoo Finance

Urticaria Day: Raising Awareness of Symptoms and Treatment

Washington, DC, Oct. 01, 2025 (GLOBE NEWSWIRE) -- On this Urticaria Day (UDAY), the Asthma and Allergy Foundation of America (AAFA), We CU, and The Mast Cell Disease Society (TMS) aim to raise ...
Pharmaceutical Technology on MSN

Dupixent gains chronic spontaneous urticaria indication in Europe

The approval marks the first for a targeted treatment in chronic spontaneous urticaria in Europe in over a decade.

Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval ...

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years ...
Medscape

Early Response to Omalizumab Linked to Long-Term Treatment Success in Chronic Spontaneous Urticaria

Patients with chronic spontaneous urticaria who respond rapidly to omalizumab show longer treatment persistence and require ...
MedPage Today

For Your Patients: Living With Chronic Hives

The reality of living with chronic hives -- which by definition last for 6 weeks or longer and have no apparent specific trigger -- can be very challenging. About half of people with "chronic ...
Medscape

First-Time Generic Approvals: Cafcit, Claritin Hives Relief Syrup, Dermatop

September 29, 2006 —The US Food and Drug Administration (FDA) has approved first-time generic formulations for caffeine citrate 10-mg/mL intravenous injection and 10-mg/mL oral solution for the ...
PharmiWeb

Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years ...